Researchers at The Wistar Institute and the University of South Florida have advanced a novel compound that specifically targets the endoplasmic reticulum (ER) stress response that is frequently hyperactivated in cancer and promotes survival of cancer cells during stressful conditions. The new compound has unique chemical properties that allow for precise activation and can be used for tracking its activity in vivo thanks to the emission of fluorescence.
Research was published online in the Journal of Medicinal Chemistry.
The ER is a cellular structure that oversees protein folding and assembly, and it activates stress response mechanisms in response to the accumulation of misfolded proteins or other stressful conditions, including low oxygen.
“Certain cancers rely on the protective role of the ER stress response to sustain their growth in stressful environmental conditions,” said Chih-Chi Andrew Hu, Ph.D., associate professor in Wistar’s Immunology, Microenvironment & Metastasis Program, and co-lead author on the study with Juan R. Del Valle, Ph.D., from the University of South Florida. “We and other groups showed that genetically and pharmacologically targeting the ER is a very effective way to attack various tumors.”
The Hu lab has been actively advancing a research program for development of compounds to block vital functions of the ER stress response, specifically inhibitors of the IRE1 protein that senses the ER stress and responds by activating a cascade of cellular events. In addition to inducing tumor cell apoptosis, these compounds activate antitumor T-cell function and inhibit tumor-associated immunosuppressive cells in vivo in mouse models, resulting in tumor shrinkage.
“This class of inhibitors has shown therapeutic promise in several cancer types, including chronic lymphocytic leukemia and Burkitt lymphoma,” said Hu. “Therefore, we are very interested in advancing them to the clinic.”
In this study, through a series of chemical modifications, Hu and collaborators created a molecule called PC-D-F07 that is pharmacologically inactive and requires UV irradiation to be “turned on” and converted into the active D-F07, which is a very potent inhibitor of IRE-1 function.
The novel prodrug strategy enhances the efficacy of IRE-1 inhibitors and allows fine control of their activity at a precise time and location by UV irradiation. Importantly, once active, D-F07 emits fluorescence that can be tracked in cells and potentially in vivo, providing a real-time therapy readout. This new strategy for stimulus-mediated release of pharmacological activity provides a promising platform to target the ER stress response for anticancer therapy and for developing other potent inhibitors.
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Megadeth’s David Ellefson opens up about Dave Mustaine’s cancer diagnosis on June 18, 2019 at 5:08 pm
Following yesterday’s announcement that Dave Mustaine of Megadeth has been diagnosed with throat cancer, bassist David Ellefson spoke with The Classic Metal Show, discussing the future of the band, ... […]
- Another cancer-causing chemical found in widely used blood-pressure pills on June 18, 2019 at 3:58 pm
Online pharmacy Valisure has discovered another cancer-causing chemical in blood-pressure pills ... patient's doctor or pharmacist provides a safe replacement or a different treatment option," the FDA ... […]
- Jean Rounds, wife of Sen. Mike Rounds, to begin cancer treatment for aggressive tumor on June 18, 2019 at 11:36 am
Jean Rounds, wife of Sen. Mike Rounds, to begin cancer treatment for aggressive tumor She will begin treatment this week at the Mayo Clinic in Rochester, Minnesota. Check out this story on argusleader ... […]
- Doctors Share What the Future of Skin Cancer Treatment Looks Like on June 18, 2019 at 8:57 am
This article first appeared in the Summer 2019 issue of NewBeauty. Click here to subscribe. From 3-D printing to matrix magic, the treatment for skin cancer keeps improving. And, while New York ... […]
- Royal Oak fitness trainer, 71, works through breast cancer treatment on June 18, 2019 at 7:52 am
With a toned physique that women half her age envy, personal fitness trainer Nancy Simpson, 71, helps her clients move more and gain strength. The Royal Oak resident practices what she teaches by ... […]
- New methods from material sciences find their way into cancer research on June 18, 2019 at 7:15 am
This pilot work shows how the mobility of water molecules confined in cancer cells changes when subjected to treatment with a chemotherapy drug. This proposed methodology holds potential for ... […]
- Pfizer buys cancer treatment innovator Array BioPharma for $11 billion on June 18, 2019 at 4:44 am
Pfizer Inc. announced on Monday it would buy Array Biopharma Inc. for $11.4 billion in cash. This would give the New York-based pharmaceutical giant access to a whole other product pipeline — ... […]
- Working together, data scientists and cancer researchers can transform cancer treatment on June 18, 2019 at 1:50 am
At a time when data and data science are increasingly essential to improving cancer care, oncologists and cancer researchers often lack the training needed to understand and leverage the data to their ... […]
- Researchers find way to reinvigorate exhausted immune cells and stop cancer on June 18, 2019 at 12:30 am
With this knowledge, investigators now have a way to accurately identify immune cells that are exhausted in a tumor or site of an infection, which could allow clinicians to improve the effectiveness ... […]
- AstraZeneca's Lynparza Gets EU Nod as First-Line Ovarian Cancer Maintenance Treatment on June 17, 2019 at 11:47 pm
(Reuters) - British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European ... […]
via Bing News